(16 April 2020) Ivermectin- Use requires careful risk–benefit considerations
Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency
http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0271
Extreme due diligence and regulatory review are needed before testing ivermectin in severe disease for following 3 points,
- Neurotoxicity
- Concurrent use of antiretrovirals
- Doses required to reach levels effective against SARS-CoV 2